Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1495 views | HTML 2032 views | ?
Simona Daniele1,2,*, Elisabetta Barresi1,*, Elisa Zappelli1, Luciana Marinelli3, Ettore Novellino3, Federico Da Settimo1, Sabrina Taliani1, Maria L. Trincavelli1 and Claudia Martini1
1 Department of Pharmacy, University of Pisa, Pisa, Italy
2 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
3 Department of Pharmacy, University of Naples Federico II, Napoli, Italy
* These authors have contributed equally to this work
Maria Letizia Trincavelli, email:
Sabrina Taliani, email:
Keywords: murine double minute 2, translocator protein, long-lasting inhibitors, glioblastoma multiforme, extracellular signal regulated kinases
Received: September 01, 2015 Accepted: January 03, 2016 Published: January 09, 2016
The development of multi-target drugs and irreversible modulators of deregulated signalling proteins is the major challenge for improving glioblastoma multiforme (GBM) treatment. Reversible single-target drugs are not sufficient to sustain a therapeutic effect over time and may favour the activation of alternative signalling pathways and the onset of resistance phenomena. Thus, a multi-target compound that has a long-lasting mechanism of action might have a greater and longer life span of anti-proliferative activity. Recently, a dual-target indol-3ylglyoxyldipeptide derivative, designed to bind to the Translocator Protein (TSPO) and reactivate p53 function via dissociation from its physiological inhibitor, murine double minute 2 (MDM2), has been developed as a potent GBM pro-apoptotic agent. In this study, this derivative was chemically modified to irreversibly bind MDM2 and TSPO. The new compound elicited a TSPO-mediated mitochondrial membrane dissipation and restored p53 activity, triggering a long-lasting apoptosis of GBM cells. These effects were sustained over time, involved a stable activation of extracellular signal regulated kinases and were specifically observed in cancer cells, in which these protein kinases are deregulated. Dual-targeting and irreversible binding properties combined in the same molecule may represent a useful strategy to overcome the time-limited effects elicited by classical chemotherapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.